Axsome Therapeutics IncAXSM
Price$184.39

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $776.6M+101.3% YoYTTM through 30 Jun 2026
Net Income -$191.6MTTM through 30 Jun 2026
Free Cash Flow -$72MTTM through 30 Jun 2026

Margins

Current
Gross Margin92.3%
EBITDA Margin-23.1%
Operating Margin-32.0%
Net Margin-24.7%

Returns

-230.1%ROE
-25.2%ROA

Balance Sheet Health

Debt / Equity3.44x
Current Ratio1.43x
Net Debt-$131.9Mnet cash position
Cash & Equivalents$319.9M

Quality Metrics

Altman Z-Score7.32
Piotroski F-Score5 / 9
FCF Margin-9.3%
Rule of 4015.8
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $638.5M
Diluted EPS-$3.75TTM
'20'21'22'23'24'25
FY2025: $-3.68

Dividend

No dividend

Capital Allocation

R&D Spend$187.9M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.